This article was originally published in The Tan Sheet
Naturex acquires Decas to enter UTI ingredient market; TSI finalizes Yessamin deal; NattoPharma gains U.S. patent for vitamin K2; DSM appoints Goppelsroeder nutritionals head; more news in brief.
You may also be interested in...
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.
Medical device regulations that were set in place by the US FDA in the 1990s are evolving with the emergence of digital-health products and their iterative nature, medtech consultant Jon Speer says. Check out his comment here.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?